Vivacelle Bio, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Vivacelle Bio, Inc. - overview
Established
2013
Location
Shreveport, LA, US
Primary Industry
Biotechnology
About
Founded in 2013 and based in Los Angeles, US, Vivacelle Bio, Inc. operates as a biotechnology platform that develops nanoparticle technology for resuscitation fluids. The company was founded by Cuthbert Simpkins, along with other co-founders Harven DeShiel (CEO), and Krishna Talluri. In February 2024, the firm raised USD 20 million in Series B funding from investors.
The company provides two products, VBI-S and VBI-1, that use nitric oxide redistribution to treat hemorrhagic and septic shock and may lessen reperfusion injury. The VBI-1 is a colloid non-blood volume expander and VBI-S is targeting hypovolemia due to sepsis/septic shock. The company plans to use the February 2024 funding to support its research and development of resuscitation fluids.
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.vivacellebio.com
Verticals
Nanotechnology
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.